The heart in mixed connective tissue disorder

Template:WikiDoc Cardiology News Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Associate Editor: Cafer Zorkun, M.D., Ph.D. [2]

Overview[edit | edit source]

In 1972, Sharp et al Žfirst described Mixed Connective Tissue Disorder (MCTD) as a distinct rheumatic disease with overlapping features of systemic lupus erythematosus (SLE), polymyositis (PM), and progressive systemic sclerosis (PSS) associated with antibodies to RNAse sensitive extractable nuclear antigen. When the antigen was subsequently characterized as polypeptides on the U1 ribonuclear protein component of the splicesosome (U1RNP), MCTD became the first rheumatic disease syndrome to be defined by a serologic test.^[1]

In addition to its rheumatic features, Mixed Connective Tissue Disorder (MCTD) has a number of cardiac manifestations including pericarditis, pericardial effusion, myocarditis, ventricular hypertrophy, ventricular dilatation, cardiac conduction disturbances, and vascular intimal hyperplasia. ^[2]

In one study evaluating 38 patients with Mixed Connective Tissue Disorder (MCTD), four of the Žfive patients who died underwent an autopsy. All four cases showed epicardial and intramural coronary intimal proliferation.^[3] Interestingly, none of these patients had pathologic evidence of myocardial infarction. In fact, in the result of same study stated that there were no coronary arterial thrombi or intimal plaques to suggest evidence of atherosclerosis.

In a similar follow-up study of 14 children with Mixed Connective Tissue Disorder (MCTD), arterial intimal hyperplasia and no evidence of myocardial damage was demonstrated in the 2 hearts undergoing autopsy.^[4]

From the original 25 patients with Mixed Connective Tissue Disorder (MCTD) described by Sharp et al, a 4-5 year follow-up study discovered that eight patients died but only one death was attributed to a myocardial infarction.^[5]

While arterial intimal hyperplasia is well described in patients with Mixed Connective Tissue Disorder (MCTD), the progression to an acute coronary syndrome (ACS) appears to be uncommon.

Histopathological Findings[edit | edit source]

There are no specific histologic findings that aid in the diagnosis of Mixed Connective Tissue Disorder as a separate autoimmune disease. For example, nephritis in MCTD is usually indistinguishable from lupus nephritis.

Symptoms of MCTD[edit | edit source]

Common symptoms[edit | edit source]

• Raynaud’s phenomenon

• Swollen fingers or hands

Anti–U1 small nuclear RNP positive[edit | edit source]

Mixed findings[edit | edit source]

A.Systemic lupus erythematosus–like findings

• Polyarthritis

• Lymphadenopathy

• Facial erythema

• Pericarditis or pleuritis

• Leukopenia (<4,000/mm3) or thrombocytopenia (<100,000/mm3)

B.Progressive Systemic Sclerosis–like findings

• Sclerodactyly

• Pulmonary fibrosis, restrictive changes of the lung (forced vital capacity <80% of predicted), or reduced carbon monoxide diffusing capacity (<70% of predicted)

• Hypomotility or dilatation of esophagus

C.Polymyositis-like findings

• Muscle weakness

• Elevated serum level of muscle enzymes (creatine kinase)

• Myogenic pattern on electromyogram

Diagnosis of MCTD[edit | edit source]

A. Kasukawa criteria

1. Presence of 1 or both common symptoms listed above
2. Positive anti–U1 snRNP antibody
3. Presence of 1 or more findings in at least 2 of the 3 disease categories under “mixed findings”

MCTD will be diagnosed when all 3 conditions are fulfilled.^{[6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17]}

B. Sharp criteria^[18]

• Definite diagnosis requires 4 major criteria with positive anti-U1 RNP greater than 1:4000 and a negative anti-Sm Ab. U1 RNP is the specific RNP protein associated with this syndrome.

• Probable diagnosis requires either 3 major criteria or 2 major criteria (which must come from the first 3 major criteria listed) and 2 minor criteria plus an anti-U1 RNP greater than 1:1000.

• Possible diagnosis requires 3 major criteria without serologic evidence of disease or, if anti-U1 RNP is greater than 1:100, 2 major criteria or 1 major and 3 minor criteria.

• Major criteria are severe myositis, pulmonary involvement (diffusing capacity of lung for carbon monoxide 70% of normal, pulmonary hypertension, proliferating vascular lesions on lung biopsy), Raynaud phenomenon or esophageal hypomotility, swollen hands or sclerodactyly, and highest observed anti-U1 RNP (>1:10.000) with negative anti-Sm Ab.

• Minor criteria are alopecia, leukopenia (4000 WBC/mL), anemia (<10 g/dL for females, <12 g/dL for males), pleuritis, pericarditis, arthritis, trigeminal neuralgia, malar rash, thrombocytopenia (<100.000/mL), mild myositis, and history of swollen hands.

C. Alarcon-Segovia and Villareal classification and diagnostic criteria ^[19]

• Serologic criterion is a positive anti-RNP at a titer of 1:1600 or higher.
• Clinical criteria (at least 3) are edema of the hands, Raynaud phenomenon (i.e., 2 or 3 color changes), acrosclerosis, synovitis, and myositis (laboratory or biopsy evidence).

Cardiac Involvement in MCTD[edit | edit source]

Cardiovascular abnormalities associated with mixed connective tissue disease are rare. Presence of any of the complications listed below indicates unfavorable prognosis;

• Acute pericarditis and/or pericardial effusion,

• Mitral valve prolapse,

• Intimal hyperplasia of coronary arteries,

• Perivascular and myocardial leukocytic infiltrates,

• Pulmonary hypertension.

• Coronary Artery Disease: Although it is rarer, ACS may occur secondary to vascular changes and underlying CAD. The youngest patient with MCTD and ACS in literature was 18 years old. ^[20]

References[edit | edit source]

Template:Diseases of the musculoskeletal system and connective tissue

Template:WikiDoc Sources